<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Oncolytic Viruses: From History to Where We Go Next

One of the more innovative weapons in our anticancer armamentarium has to be oncolytic viruses. Their rationale as an anticancer therapy is that once a cancer cell is infected, the virus replicates until the cancer cell eventually dies by lysis. As the virus has replicated, this leaves more virions to then infect and kill other cancer cells. As cell lysis is also an immunogenic death, the immune system is also potentially stimulated to target cancer cells too.

Using Viruses as Anticancer Agents

As with many (dare I say most) innovative cancer therapies, the idea of using viruses as anticancer agents was born from serendipity. As early as the turn of the 20th century there were numerous anecdotal reports of spontaneous cancer remissions following viral infections. One case of note was the initiation of extensive tumor necrosis in a cervical cancer patient who had been treated prophylactically with a live-attenuated rabies vaccine following a dog bite. This is of interest because this might represent the first controlled, albeit unintentional, application of a virus based therapy for cancer.

Clinical investigation into viruses as a therapeutic for cancer continued in a haphazard manner throughout the 1950’s to the 1980’s, at which point the subsequent revolution in molecular biology allowed for both a deeper understanding of the biology of viruses and their subsequent engineering.

Onyx-015

The development of Onyx-015, an adenovirus, represented a watershed moment in oncolytic virus therapy. This was the first engineered virus specifically designed for anticancer therapy. While a thorough description of Onyx-015 development is beyond the scope of this blog, you can explore the story and the concept of conditionally replicative viruses here. It is truly an elegant application at the convergence of Virology and Oncology.

As often happens in drug development, work on Onyx-015 was stopped due to acquisition and corporate portfolio prioritization. Shanghai Sunway Biotech picked up the conditionally replicative adenovirus effort, and in 2005 received regulatory approval in China for Oncorine, a close relative of Onyx-015.

T-Vec

T-Vec, also known as talimogene laherparepvec (now there’s a mouthful) is a Herpes virus engineered to overexpress Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). The inclusion of GM-CSF is hypothesized to stimulate the immune system further following lytic cell death, although direct evidence for this is lacking in the literature.

T-Vec is a locally administered (i.e. intratumoral) therapy with clinically demonstrated overall survival benefit in advanced, metastatic disease when compared to systemic GM-CSF administration. Importantly, in one trial, 15% of non-injected visceral metastases also showed evidence of response, which is taken as the clinical evidence of the generation of anticancer immunity. T-Vec was FDA approved in 2015 for the treatment of melanoma and subsequently approved in Europe by the EMA.

Oncolytic Virus Therapy Challenges

There’s always a downside, right? One of the current challenges with oncolytic virus therapy is our ally, the immune system. While an underlying goal for this therapy is to drive the immune system against the cancer, the therapeutic agent remains a virus, something that the immune system is exquisitely tuned to combat. Thus, in many cases the patient will generate a so-called anti-drug antibody (ADA) response.

The ADA response has a minimal influence on Oncolytic virus activity in locally administered therapy (i.e. T-Vec). However, in a systemic application the presence of ADA can drive the dose required to impractical and potentially dangerous levels.

Combining Oncolytic Viruses and Immunomodulatory Agents

With the current success of immune based therapy it is logical to consider the combination of oncolytic virus therapy with an immunomodulatory agent. A number of oncolytic virus therapies, approved and experimental, are currently in clinical trials in combination with checkpoint inhibitors. Stay tuned for further blogs as the data from these trials become realized.

Further Reading

To read more on this topic, the following publications could be of interest:

https://www.ncbi.nlm.nih.gov/pubmed/26280277
https://www.ncbi.nlm.nih.gov/pubmed/27486853
https://www.ncbi.nlm.nih.gov/pubmed/26098919


Related Posts